VKTX
Company Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (359.64M) | (109.96M) | (85.89M) | (68.87M) | (54.99M) | (39.49M) | (25.78M) | (22.06M) | (20.58M) | (14.73M) | (23.40M) | (21.88M) |
| EPS | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 | -0.36 | -0.38 | -0.79 | -0.90 | -3.68 | -5.08 |
| Free Cash Flow | (278.69M) | (87.79M) | (73.38M) | (48.40M) | (47.59M) | (21.78M) | (24.75M) | (18.75M) | (14.76M) | (11.07M) | N/A | N/A |
| FCF / Share | -2.47 | -0.81 | -0.78 | -0.63 | -0.62 | -0.30 | -0.34 | -0.33 | -0.57 | -0.68 | N/A | N/A |
| Operating CF | (278.69M) | (87.79M) | (73.38M) | (48.40M) | (47.59M) | (21.78M) | (24.75M) | (18.75M) | (14.76M) | (11.07M) | N/A | N/A |
| Total Assets | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M | 256.50M | 284.26M | 302.31M | 22.12M | 14.54M | N/A | N/A |
| Total Debt | 137,000 | 1.12M | 1.26M | 1.56M | 29,000 | 359,000 | 662,000 | 0 | 3.45M | 3.27M | N/A | N/A |
| Cash & Equiv | 165.81M | 26.68M | 55.52M | 36.63M | 26.37M | 29.12M | 8.38M | 24.78M | 8.99M | 3.08M | N/A | N/A |
| Book Value | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M | 244.34M | 277.12M | 297.75M | 13.46M | 8.04M | N/A | N/A |
| Return on Equity | -0.56 | -0.12 | -0.25 | -0.47 | -0.27 | -0.16 | -0.09 | -0.07 | -1.53 | -1.83 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (158.32M) | (157.66M) | (90.79M) | (65.56M) | (45.63M) | (35.42M) | (24.94M) | (22.25M) | (27.36M) | (24.61M) | (22.53M) | (19.23M) |
| EPS | -1.37 | -1.38 | -0.81 | -0.58 | -0.41 | -0.32 | -0.22 | -0.20 | -0.26 | -0.25 | -0.23 | -0.19 |
| Free Cash Flow | (113.98M) | (85.29M) | (94.00M) | (47.06M) | (52.33M) | (31.18M) | (21.96M) | (28.51M) | (6.13M) | (17.64M) | (19.66M) | (11.44M) |
| FCF / Share | -0.99 | -0.75 | -0.84 | -0.42 | -0.47 | -0.28 | -0.20 | -0.26 | -0.06 | -0.18 | -0.20 | -0.12 |
| Operating CF | (113.98M) | (85.29M) | (94.00M) | (47.06M) | (52.33M) | (31.18M) | (21.96M) | (28.51M) | (6.13M) | (17.64M) | (19.66M) | (11.44M) |
| Total Assets | 608.24M | 715.73M | 739.41M | 827.85M | 866.99M | 908.32M | 937.89M | 946.84M | 967.52M | 368.49M | 382.66M | 400.69M |
| Total Debt | 0 | 137,000 | 755,000 | 878,000 | 1.00M | 1.12M | 1.24M | 1.10M | 1.18M | 1.26M | 1.34M | 1.41M |
| Cash & Equiv | 118.12M | 165.81M | 100.38M | 33.88M | 37.94M | 26.68M | 50.35M | 43.91M | 195.58M | 55.52M | 37.19M | 69.52M |
| Book Value | 501.92M | 639.06M | 713.03M | 795.46M | 846.92M | 880.28M | 911.45M | 920.98M | 933.89M | 348.42M | 368.24M | 386.12M |
| Return on Equity | -0.32 | -0.25 | -0.13 | -0.08 | -0.05 | -0.04 | -0.03 | -0.02 | -0.03 | -0.07 | -0.06 | -0.05 |
